ESPR
Income statement / Annual
Last year (2023), Esperion Therapeutics, Inc.'s total revenue was $116.33 M,
an increase of 54.14% from the previous year.
In 2023, Esperion Therapeutics, Inc.'s net income was -$209.25 M.
See Esperion Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$116.33 M
|
$75.48 M
|
$78.45 M
|
$227.55 M
|
$148.36 M
|
$184.47 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$43.27 M |
$26.97 M |
$14.22 M |
$2.39 M |
$175.61 M |
$265,000.00 |
$258,000.00 |
$252,000.00 |
$236,000.00 |
$0.00 |
| Gross Profit |
$73.07 M |
$48.51 M |
$64.23 M |
$225.16 M |
-$27.25 M |
$184.21 M |
-$258,000.00 |
-$252,000.00 |
-$236,000.00 |
$0.00 |
| Gross Profit Ratio |
0.63 |
0.64 |
0.82 |
0.99 |
-0.18 |
1 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$86.11 M
|
$118.93 M
|
$105.98 M
|
$146.94 M
|
$175.61 M
|
$171.49 M
|
$147.60 M
|
$57.87 M
|
$29.80 M
|
$25.30 M
|
| General & Administrative
Expenses |
$126.92 M
|
$97.78 M
|
$171.29 M
|
$180.32 M
|
$65.85 M
|
$33.10 M
|
$21.38 M
|
$18.28 M
|
$20.24 M
|
$10.92 M
|
| Selling & Marketing
Expenses |
$15.60 M
|
$11.30 M
|
$13.70 M
|
$19.30 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$142.52 M
|
$109.08 M
|
$184.99 M
|
$199.62 M
|
$65.85 M
|
$33.10 M
|
$21.38 M
|
$18.28 M
|
$20.24 M
|
$10.92 M
|
| Other Expenses |
$0.00 |
$2.65 M |
$3.98 M |
$515,000.00 |
$4.06 M |
$2.78 M |
$2.19 M |
$1.55 M |
$776,000.00 |
$119,000.00 |
| Operating Expenses |
$271.90 M |
$228.01 M |
$290.96 M |
$346.55 M |
$241.47 M |
$204.59 M |
$168.98 M |
$76.15 M |
$50.04 M |
$36.22 M |
| Cost And Expenses |
$271.90 M |
$254.98 M |
$305.18 M |
$348.94 M |
$241.47 M |
$204.59 M |
$168.98 M |
$76.15 M |
$50.04 M |
$36.22 M |
| Interest Income |
$0.00 |
$2.60 M |
$112,000.00 |
$600,000.00 |
$4.00 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$58.98 M |
$56.81 M |
$46.35 M |
$22.67 M |
$8.12 M |
$100,000.00 |
$198,000.00 |
$376,000.00 |
$520,000.00 |
$270,000.00 |
| Depreciation &
Amortization |
$164,000.00
|
$500,000.00
|
$612,000.00
|
$547,000.00
|
$319,000.00
|
$265,000.00
|
$258,000.00
|
$252,000.00
|
$236,000.00
|
$160,000.00
|
| EBITDA |
-$150.11 M
|
-$176.35 M
|
-$222.14 M
|
-$120.33 M
|
-$88.73 M
|
-$204.32 M
|
-$166.53 M
|
-$74.35 M
|
-$49.03 M
|
-$36.06 M
|
| EBITDA Ratio |
-1.29 |
-2.34 |
-2.84 |
-0.53 |
-0.6 |
-1.11 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-1.34
|
-2.38
|
-2.89
|
-0.53
|
-0.63
|
-1.11
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$53.69 M
|
-$54.16 M
|
-$42.38 M
|
-$22.16 M
|
-$4.06 M
|
$2.78 M
|
$1.99 M
|
$1.17 M
|
$256,000.00
|
-$151,000.00
|
| Income Before Tax |
-$209.25 M |
-$233.66 M |
-$269.11 M |
-$143.55 M |
-$97.17 M |
-$201.81 M |
-$166.99 M |
-$74.98 M |
-$49.78 M |
-$36.38 M |
| Income Before Tax Ratio
|
-1.8
|
-3.1
|
-3.43
|
-0.63
|
-0.65
|
-1.09
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
$54.16 M |
$49.72 M |
$22.64 M |
$11.86 M |
$2.88 M |
$2.13 M |
$1.67 M |
$1.06 M |
$229,000.00 |
| Net Income |
-$209.25 M |
-$287.82 M |
-$318.82 M |
-$166.19 M |
-$109.02 M |
-$201.81 M |
-$166.99 M |
-$74.98 M |
-$49.78 M |
-$36.38 M |
| Net Income Ratio |
-1.8 |
-3.81 |
-4.06 |
-0.73 |
-0.73 |
-1.09 |
0 |
0 |
0 |
0 |
| EPS |
-2.03 |
-4.33 |
-11.03 |
-6.05 |
-4.02 |
-7.54 |
-6.98 |
-3.33 |
-2.26 |
-2.22 |
| EPS Diluted |
-2.03 |
-4.33 |
-11.03 |
-6.05 |
-4.02 |
-7.54 |
-6.98 |
-3.33 |
-2.26 |
-2.22 |
| Weighted Average Shares
Out |
$103.11 M
|
$66.41 M
|
$28.90 M
|
$27.47 M
|
$27.09 M
|
$26.75 M
|
$23.93 M
|
$22.54 M
|
$22.02 M
|
$16.37 M
|
| Weighted Average Shares
Out Diluted |
$103.11 M
|
$66.41 M
|
$28.90 M
|
$27.47 M
|
$27.09 M
|
$26.75 M
|
$23.93 M
|
$22.54 M
|
$22.02 M
|
$16.37 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
